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Abstract 23 
The colorectal adenoma-carcinoma sequence has provided a paradigmatic framework for 24 
understanding the successive somatic genetic changes and consequent clonal expansions 25 
leading to cancer. As for most cancer types, however, understanding of the earliest phases of 26 
colorectal neoplastic change, which may occur in morphologically normal tissue, is 27 
comparatively limited. Here, we whole genome sequenced hundreds of normal crypts from 28 
42 individuals. Signatures of multiple mutational processes were revealed, some ubiquitous 29 
and continuous, others only found in some individuals, in some crypts or during certain 30 
periods of life. Likely driver mutations were present in ~1% of normal colorectal crypts in 31 
middle-aged individuals, indicating that adenomas and carcinomas are rare outcomes of a 32 
pervasive process of neoplastic change across morphologically normal colorectal epithelium. 33 
Colorectal cancers exhibit substantially elevated mutation burdens relative to normal cells. 34 
Sequencing normal colorectal cells provides quantitative insights into the genomic and clonal 35 




Sequencing of >20,000 cancers has identified the repertoire of driver mutations in cancer 40 
genes converting normal cells into cancer cells and revealed the mutational signatures of the 41 
underlying biological processes generating somatic mutations1,2. Cancers are, however, end 42 
stages of an evolutionary process operating within cell populations and commonly arise 43 
through the accumulation of multiple driver mutations engendering a series of clonal 44 
expansions. Understanding this progression has depended on identifying somatic mutations in 45 
morphologically abnormal neoplastic proliferations representing intermediate stages between 46 
normal and cancer cells.3 47 
 48 
As for most cancer types, however, the earliest stages of progression to colorectal cancer 49 
remain less well understood. The driver mutation that first sets a colorectal epithelial cell on 50 
the path to cancer is likely caused by mutational processes operative in normal cells, of which 51 
there is limited understanding. The nature and numbers of the earliest neoplastic clones with 52 
driver mutations, which conceivably are morphologically indistinguishable from normal 53 
cells, are similarly unclear. In large part, these deficiencies are due to the technical challenge 54 
of identifying somatic mutations in normal tissues, which are composed of myriad 55 
microscopic cell clones. Several different approaches have been adopted to address this4-14, 56 
revealing signatures of common somatic mutational processes in normal cells of the small 57 
and large intestine, liver, blood, skin, and nervous system. Thus far, however, studies have 58 
not been of sufficient scale to characterise variation in signature activity or detect less 59 
frequent processes4-14. Remarkably high proportions of normal skin, oesophageal, and 60 
endometrial epithelial cells have been shown to be members of clones already carrying driver 61 
mutations10,11,15,16, and large mutant clones have been detected in blood17-20. The extent of 62 
this phenomenon in the colon, an organ with a high cancer incidence, has not been 63 
investigated. 64 
 65 
Colonic epithelium is a contiguous cell sheet organised into ~15,000,000 crypts each 66 
composed of ~2,000 cells21. Towards the base of each crypt resides a small number of stem 67 
cells ancestral to the maturing and differentiated cells in the crypt22. These stem cells 68 
stochastically replace one another through a process of neutral drift23,24 such that all stem 69 
cells, and thus all cells, in a crypt derive from a single ancestor stem cell that existed in recent 70 
years25-27. The somatic mutations that were present in this ancestor are thus found in all 71 
~2,000 descendant cells and can be revealed by DNA sequencing of an individual crypt. 72 
These stem cells are thought to be the cells of origin of colorectal cancers28. To characterise 73 
the earliest stages of colorectal carcinogenesis, somatic mutation burdens, mutational 74 
signatures, clonal dynamics, and the frequency of driver mutations in normal colorectal 75 
epithelium were explored by sequencing individual colorectal crypts.  76 
 77 
Results 78 
Somatic mutations and mutational signatures 79 
2,035 individual colonic crypts from the normal epithelium of 42 individuals aged 11 to 78, 80 
of whom 15 had a history of colorectal cancer and 27 did not (Methods, Supplementary Table 81 
1), were isolated using laser capture microdissection and sequenced. The distribution of 82 
mutation allele fractions from whole genome sequencing of 571 individual crypts showed 83 
that crypts were derived from a single ancestral stem cell (Extended Data Fig. 1d), and 84 
simulations indicated that ~90% of mutations called were fully clonal (Supplementary 85 
Results 2). There was substantial variation in mutation burdens between individual crypts, 86 
ranging from 1,508 to 15,329 for individuals in their sixties, which was not obviously 87 
attributable to technical factors. To explore the biological basis of this variation we extracted 88 
mutational signatures and estimated the contribution of each to the mutation burden of every 89 
crypt (Methods, Supplementary Results 1). 90 
 91 
Nine single base substitution (SBS), six doublet base substitution (DBS), and five small indel 92 
(ID) mutational signatures were found. Of these, 14 closely matched (Methods) a known 93 
reference signature (SBS1, SBS2, SBS5, SBS13, SBS18, DBS2, DBS4, DBS6, DBS8, 94 
DBS9, DBS11, ID1, ID2, and ID5, nomenclature as in Alexandrov et al1) and six did not 95 
(SBSA, SBSB, SBSC, SBSD, IDA, and IDB) (Fig. 1, Extended Data Fig. 2-4). Thus, new 96 
mutational signatures were extracted despite extensive prior analysis of cancers, perhaps due 97 
to masking by the comparative complexity of signature mixtures present in cancer genomes. 98 
 99 
Ubiquitous mutational signatures 100 
11 signatures (SBS1, SBS5, SBS18, DBS2, DBS4, DBS6, DBS9, DBS11, ID1, ID2, and 101 
ID5) were found in >85% of crypts and are here termed “ubiquitous”. All have been 102 
previously described1.  103 
 104 
SBS1 is characterised by C>T substitutions at NCG trinucleotides (the mutated base is 105 
underlined) and is likely due to deamination of 5-methylcytosine. Its mutation load correlated 106 
linearly with age (Fig. 2). There was, however, variation in SBS1 mutation burdens between 107 
crypts from the same individual (p=2.25e-27). This was due, in part, to different SBS1 108 
mutation rates in different colonic sectors, with mean rates across individuals of 16.8 109 
mutations per year (95% CI 15.2-18.3) in the right (ascending and caecum), 16.1 (95% CI 110 
14.4-17.5) in the transverse, and 12.8 (95% CI 11.1-14.4) in the left (descending and 111 
sigmoid) colon. The SBS1 mutation rate in the terminal ileum was 12.7 (95% CI 10.6-14.9) 112 
(Supplementary Results 1). SBS5 is a flat, featureless signature of unknown cause and SBS18 113 
is characterised by C>A mutations, which may be due to DNA damage by reactive oxygen 114 
species29,30. Their mutation burdens correlated with age, with the same ordering of sector 115 
differences as SBS1 (p=9.89e-26 for SBS5, p=5.43e-22 for SBS18). Even after taking 116 
anatomical location and age into account, differences in mutation burden remained between 117 
different crypts, notably for SBS18 (Fig. 2, Extended Data Fig. 9, Extended Data Fig. 6al). 118 
Combining ubiquitous SBS mutational signatures, and averaging over anatomical sites, the 119 
mutation rate was 43.6 mutations per year, comparable with previous estimates4. 120 
 121 
DBS2, DBS4, DBS6, DBS9, and DBS11 were tightly correlated in all colonic crypts. ID1, 122 
ID2, and ID5, which are characterised by insertions and deletions of a single T and may be 123 
the consequence of slippage during DNA replication, all accumulated linearly with age with 124 
the same order of sector differences as SBS1 (p=1.66e-05 for ID1, p=4.53e-06 for ID2, and 125 
p=4.53e-06 for ID5) (Supplementary Results 1, Extended Data Fig. 5). 126 
 127 
The correlations of ubiquitous signatures with age indicate that the mutational processes 128 
underlying them operate throughout life, in all individuals and all colorectal stem cells. 129 
However, the results also suggest that differences in physiology and/or microenvironment 130 
(and potentially age of the most recent common ancestor of crypts27) between different 131 
sectors of the colon cause measurable differences in somatic mutation rates.  132 
 133 
Sporadic mutational signatures 134 
Nine signatures (SBS2, SBS13, SBSA-D, DBS8, and IDA-B) were present only in a subset 135 
of individuals and/or a subset of crypts and are termed “sporadic”. All were novel, except for 136 
SBS2, SBS13 and DBS8. SBS2 and SBS13 are characterised by C>T and C>G mutations at 137 
TCN, are likely due to APOBEC cytidine deaminases and usually occur together31,32. They 138 
were unequivocally present in only two crypts (a colonic crypt (Extended Data Fig. ai) and an 139 
ileal crypt (Extended Data Fig. ao) from different individuals), occurring together and each 140 
accounting for over 150 mutations. To our knowledge, this is the first report that APOBEC 141 
DNA-editing of the human genome occurs in normal cells in vivo. The sequence context of 142 
these mutations in normal colon suggests that APOBEC3A is the major contributing 143 
enzyme33.  144 
 145 
Four SBS signatures that do not match the reference set, SBSA-D, were found in normal 146 
colorectal cells (SBSA has recently been reported in an oral squamous carcinoma34). SBSA is 147 
characterised by T>C at ATA, ATT, and TTT, and T>G at TTT. Its mutation burden 148 
correlated closely with that of IDA, in which single T deletions in short runs of Ts (with a 149 
mode of four) predominate, suggesting that they are due to the same underlying mutational 150 
process. SBSA was detectable in 29/42 individuals, often accounting for thousands of 151 
mutations in just a subset of crypts. It clustered spatially in the colon, with crypts from the 152 
same biopsy carrying the signature even though the mutations themselves were not shared 153 
(Supplementary Results 1, Extended Data Fig. 9). 2.5-fold more T>C mutations occurred 154 
when the T was on the transcribed than on the untranscribed strand. Transcriptional strand 155 
bias is often due to transcription coupled nucleotide excision repair acting on DNA damaged 156 
by exogenous exposures causing covalently bound bulky adducts, but can also be caused by 157 
transcription coupled DNA damage35. Assuming either is the case, damage to adenine 158 
underlies SBSA. To investigate the timing of SBSA, phylogenetic trees of mutations were 159 
constructed and the mutational signatures in each branch established (Fig. 3, Extended Data 160 
Fig. 6). SBSA was confined to early branches of these phylogenies (when these were 161 
available for analysis) (Fig. 3b, Extended Data Fig. 6 f, h, z, aa, am, ao, aq). Using the 162 
number of SBS1 mutations as indicators of real time, the mutational process underlying 163 
SBSA appears to be active before 10 years of age (Supplementary Methods, Extended Data 164 
Fig. 6aq). SBSA may therefore be caused by an extrinsic, locally acting and patchily 165 
distributed mutagenic insult occurring during childhood.  166 
 167 
SBSB was characterised by C>T at ACA, T>A at CTN, and T>G at GTG and was present in 168 
subsets of crypts from four individuals (e, aa, ai, and aj in Extended Data Figure 6), 169 
accounting for variable numbers of substitutions, with a maximum of 3,002 in one crypt. 170 
(Fig. 3c, Extended Data Fig. 6ai). In the two individuals in whom it could be timed (Extended 171 
Data Fig. 6 aa, ai, aq), it appeared – as with SBSA – to be most active in the first decade of 172 
life. SBSB correlated with DBS8 and IDB (Fig. 3c, Extended Data Fig. 9), suggesting that 173 
they are caused by the same underlying mutational process. DBS8 is composed of AC>CA 174 
and AC>CT mutations and has previously been reported in rare hypermutated cancers with 175 
no obvious cause1. IDB is dominated by deletion of a single T with no other Ts surrounding 176 
it. 177 
 178 
SBSC is characterised by one C>T mutation in CC dinucleotides. It primarily affects three 179 
crypts, with 1,050, 827, and 695 mutations respectively, from the left colon of one individual 180 
with an unremarkable history (Extended Data Fig. 9, Extended Data Fig. 6m, Supplementary 181 
Table 1). 182 
 183 
All crypts from a 66 year-old man carried many thousands of mutations of SBSD (Figure 3d, 184 
Extended Data Fig. 6ap), characterised by T>A substitutions with a transcriptional strand bias 185 
compatible with damage to adenine. This individual had been treated with multiple 186 
chemotherapeutic agents (cyclophosphamide, doxorubicin, vincristine, prednisolone, 187 
chlorambucil, bleomycin and etoposide) for lymphoma and subsequently developed caecal 188 
adenocarcinoma. SBSD resembles SBS25 (cosine similarity 0.9), previously found in 189 
Hodgkin lymphoma cell lines from two chemotherapy-treated patients31,36. To our knowledge 190 
this is the first time that the mutational consequences of chemotherapy have been 191 
demonstrated in normal human cells in vivo. The mutation burden in his colorectal epithelium 192 
was 3-5 fold higher than expected for his age, thus by extrapolation equivalent to that of a 193 
200-300 year-old.  194 
 195 
Copy number changes and structural variants 196 
Copy number changes and/or structural variants were found in 80 out of 449 (18%) evaluable 197 
crypts. Five crypts exhibited eight whole chromosome copy number increases which affected 198 
the same three chromosomes – 3, 7 and 9 – as well as the X chromosome (Extended Data 199 
Fig. 7a). Thus, copy number increases clustered in certain crypts and tended to affect certain 200 
chromosomes. No whole chromosome losses were observed. Arm-level chromosome 7 copy 201 
number increases are common in colorectal cancers37 and adenomas38. Chromosome 3 and 9 202 
copy number increases are seen in colorectal cancers, but are almost as frequently deleted37. 203 
Copy number neutral loss of heterozygosity (CNN-LOH) was observed in 12 crypts, 204 
affecting chromosomes 1p, 6p, 7p, 8q, 9q, 10q (twice), 17p, 17q, 18q, 21q and 22q (Extended 205 
Data Fig. 7c). CNN-LOH is frequently observed in colorectal cancers, although the specific 206 
changes that we observe here are not recurrent features39. Five copy number changes could be 207 
timed and all were estimated to have occurred in adulthood (Extended Data Fig. 7b). Two 208 
changes that affected the same crypt appeared to be synchronous (Supplementary Results 1). 209 
Structural variant analysis detected 48 large deletions, 18 tandem duplications, four 210 
translocations, and two inversions (Extended Data Fig 7d, Supplementary Results 1). All 211 
were private to a single crypt, except for one deletion which was present in two adjacent 212 
crypts sharing few mutations, indicating that it occurred during gestation or early childhood. 213 
 214 
Driver mutations 215 
Driver mutations are those that confer a selective advantage during cancer evolution. To 216 
search for drivers in normal colon, the whole genome sequences of 571 crypts were 217 
supplemented with targeted sequencing of 90 known colorectal cancer genes (Supplementary 218 
Table 4) in additional crypts. In total, substitutions in these genes were evaluable in 1,403 219 
crypts and indels in 1,046. Statistical analysis revealed evidence of positive selection on the 220 
recessive cancer genes AXIN2 (three truncating mutations, adjusted q value 0.004) and 221 
STAG2 (two truncating mutations, adjusted q value 0.038) indicating that these mutations are 222 
likely drivers. Additional likely drivers were identified in cancer genes with canonical 223 
missense hotspot mutations. Nine hotspot mutations in PIK3CA (E542K, R38H), ERBB2 224 
(R678Q, V842I, T862A), ERBB3 (R475W, R667L), and FBXW7 (R505C, R658Q) were 225 
observed (Extended Data Fig. 8). Given the specificity of these hotspot mutations, most are 226 
likely to be drivers. In addition, heterozygous truncating mutations were found in the 227 
recessive cancer genes ARID2, ATM (two), ATR, BRCA2, CDK12 (two), CDKN1B, RNF43 228 
(two), TBL1XR1, and TP53 (Supplementary Table 5). There was no statistical evidence for 229 
selection of truncating mutations in the set of 90 colorectal cancer genes overall. The 230 
possibility that some have conferred clonal growth advantage, however, is not excluded. 231 
None of the analysed crypts carried more than one putative driver.  232 
 233 
23 pairs of adjacent crypts shared over 100 SBS1 mutations and thus were likely to have been 234 
generated by postnatal crypt fission. Two pairs carried driver mutations (one AXIN2 nonsense 235 
mutation and one PIK3CA E542K), although the association of driver mutations with crypt 236 
fission is not significant (p=0.17). In one sister crypt the AXIN2 mutation was rendered 237 
homozygous by CNN-LOH of 17q, revealing ongoing clonal evolution in normal colon (Fig. 238 
4, Fig. 3b).  239 
 240 
On the conservative assumption that just the AXIN2 and STAG2 truncating mutations and the 241 
missense hotspot mutations in PIK3CA, ERBB2, ERBB3 and FBXW7 are drivers, ~1% of 242 
normal colorectal crypts (~150,000 crypts) in a 50-60 year old (the mean age of crypts 243 
assessed for drivers in our cohort was 53 years old) carries a driver mutation. Since in the 244 
over 70s ~40% of people have an adenoma on colonoscopy40 and ~5% of people develop 245 
colorectal cancer over their lifetime41 (and some of these may arise from more recently-246 
acquired driver mutations) only an extremely small proportion of these crypt microneoplasms 247 
becomes a macroscopically detectable adenoma (< 1/375,000) or carcinoma (< 1/3,000,000) 248 
within the following few decades. 249 
 250 
Clonal dynamics of normal epithelium 251 
The distribution of allele fractions of mutations within the crypt informs on the dynamics of 252 
stem cell turnover within the crypt. We estimate that the average number of years to the most 253 
recent common ancestor of crypts is 5.5 years (CI95 for the mean: 1-10.5 years), similar to 254 
previous estimates14. Our data are compatible with previous estimates of 7 active stem cells 255 
and 1.3 stem cell replacements per year14 or with 5 stem cells and 0.6 stem cell replacements 256 
per year42, but we cannot exclude a larger number of stem cells turning over more frequently 257 
(Extended data figure 10, Supplementary Results 2). The microdissection approach also 258 
allowed investigation of the clonal structure of colonic epithelium beyond the crypt. By 259 
comparing the genetic relatedness of crypts with their spatial relatedness, we estimate that 260 
crypts fission at a mean rate of once every 27 years (CI95: 15.9-47.6 years) (Extended data 261 
figure 10, Supplementary Results 2).  262 
 263 
Comparisons with colorectal cancer 264 
There are marked differences between the genomes of normal colorectal stem cells and those 265 
of colorectal cancers. The total mutation burdens of substitutions (10,000-20,000) and indels 266 
(1,000-2,000) found in most colorectal carcinomas1 (excluding those with hypermutator 267 
phenotypes in which it is usually >10-fold more) are higher than the ~3,000 substitutions and 268 
300 indels found in most normal crypts from 50-60 year-old individuals (Extended Data 269 
Figure 11a). These differences may be underestimated as the most recent common ancestor 270 
of cancers likely predates that of normal crypts. The high mutation burdens and associated 271 
mutational signatures of DNA mismatch repair deficiency and/or polymerase ε/δ mutations 272 
were not found in any normal colorectal crypts but are present in ~20% colorectal cancers. 273 
Equally striking is the difference between the 0-4 structural changes per normal crypt (with 274 
the majority having none (Supplementary Results 1)) and the 10s to 100s per colorectal 275 
cancer43. In all these respects, the genomes of normal crypts with driver mutations were 276 
similar to those of normal crypts without drivers (Extended Data Fig. 9). 277 
 278 
There was no difference in the burden either of sporadic or ubiquitous mutational processes 279 
between the crypts of individuals with and without a colorectal cancer (Supplementary 280 
Results 1). If differences in mutational processes in normal cells do underlie why some 281 
people develop colon cancer and others do not, these mutational processes must affect only a 282 
small proportion of crypts in the colon, or only exert subtle effects on the mutation rate such 283 
that we could not detect differences between the two groups. The increased base substitution 284 
and indel mutation loads in cancers are due to a combination of higher burdens of the 285 
ubiquitous mutational signatures found in normal crypts, additional signatures thus far found 286 
exclusively in cancers (confirming previous reports5,44) and larger numbers of copy number 287 
changes and structural variation (Extended Data Figure 11a). The causes of some of these 288 
additional mutations in cancer are known (for example, defective mismatch repair and 289 
polymerase ε/δ mutations) but the majority are uncertain. 290 
 291 
The relative frequencies of mutated cancer genes differ between colorectal 292 
adenomas/carcinomas and normal colorectal cells (p=0.003, Supplementary Results 1, 293 
Extended Data Figure 11a). In colorectal cancer, mutations in APC, KRAS and TP53 are 294 
common37, accounting for 56% of base substitution and indel drivers (Supplementary 295 
Methods) but are comparatively rare among normal crypts with driver mutations (1/14). By 296 
contrast, mutations in, for example, ERBB2 and ERBB3 are common in normal crypts with 297 
drivers (5/14) but rare in colorectal cancer (7/631). In the case of APC (but not KRAS and 298 
perhaps not TP53), biallelic inactivation may be required to confer a strong growth 299 
advantage, which helps to explain why APC may be mutated less frequently in normal colon 300 
than ERBB2/3 that require a single hit to do so. The results suggest that mutations in APC, 301 
KRAS and TP53 confer higher likelihoods of conversion to adenoma and carcinoma than 302 
mutations in ERBB2 and ERBB3 whereas the latter confer higher likelihoods of stem cells 303 
colonising crypts. There was no detectable difference in the frequency of driver mutations 304 
between individuals in our cohort who had colorectal cancer relative to those who did not 305 





This study has characterised all classes of somatic mutation in hundreds of normal colorectal 311 
epithelial stem cells. Our experimental design allows us to gain insights into different facets 312 
of the earliest stages of the clonal evolution of colorectal cancers, namely the range of 313 
mutational processes, the frequency of driver mutations, and the clonal dynamics of colonic 314 
stem cells. 315 
 316 
A substantial repertoire of base substitution and indel mutational processes is operative, some 317 
ubiquitous and some sporadic, together with relatively infrequent copy number changes and 318 
genome rearrangements. APOBEC DNA-editing occurs in normal colon, albeit only in rare 319 
cells. Many signatures, however, are of unknown aetiology and some appear to be acquired 320 
early in life. The presence of five times the age-standard mutation load in all colorectal cells, 321 
and potentially many other tissues, in an individual who had undergone chemotherapy 322 
provides new insight into the impact of such exposures and raises questions pertaining to its 323 
relationship with chemotherapy’s relatively modest impact on cancer risk45. 324 
 325 
The earliest stages of colorectal cancer development have been revealed in this manuscript. 326 
They are characterised by numerous crypts carrying driver mutations, of which only a very 327 
small fraction ever manifests as macroscopic neoplasms. Certain mutated cancer genes 328 
appear to foster this pervasive and invisible wave of microneoplastic change whereas others 329 
particularly engender progression to colorectal adenoma and cancer. The conversion of these 330 
early microneoplasms to more advanced stages of colorectal neoplasia is associated with 331 
acquisition of elevated mutational loads, composed of base substitutions, indels, structural 332 
variants and copy number changes. More extensive studies of colorectal epithelium will 333 
enable characterisation of the rarer intermediate stages between these early clones and small 334 
adenomas, and refine understanding of the development of the subset of microneoplasms 335 
with higher likelihoods of becoming carcinomas.  336 
 337 
The proportion of normal colorectal epithelial cells with driver mutations (1%) is, however, 338 
substantially lower than that of other normal tissues so far studied, notably skin (30%)10, 339 
oesophagus (>50%)16. This may be due, at least in part, to the modular structure of glandular 340 
epithelia. The small number of stem cells within a crypt diminishes the probability that a cell 341 
with a driver mutation will outcompete its wild-type neighbours. Moreover, even if it does 342 
colonise the crypt, a mutant stem cell is entombed in it unless it can overcome the largely 343 
unknown forces that govern clonal expansion through crypt fission. The lower driver burden 344 
of colon relative to endometrium11,15, which is also glandular, remains to be explored.  345 
 346 
Fundamental questions are being addressed with respect to differences in cancer incidence 347 
rates between tissues. The somatic mutation burden in colon and ileum is similar despite the 348 
substantially higher cancer incidence rate in colon (as previously noted4) and therefore does 349 
not appear to account for this difference. Whether the total burden of microneoplastic change 350 
across the colon and in other tissues more closely correlates with these differences is yet to be 351 
determined.   352 
 353 
Finally, this study provides a reference perspective on the mutational signatures and driver 354 
mutations in normal colon against which disease states of inflammatory, genetic, neoplastic, 355 
degenerative and other aetiologies can be compared. Similar surveys conducted across the 356 
range of normal cell types will inform on the universal process of somatic evolution in the 357 
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 498 
FIGURE LEGENDS 499 
 500 
Figure 1. Mutational signatures present in normal colon. a, an example SBS, DBS, and 501 
ID signature showing the categories into which mutations are divided. Later figures are 502 
shown in the same format. b, the complement of signatures in normal colonic epithelium. 503 
Known signatures are labelled according to their nomenclature in PCAWG, while novel 504 
signatures are labelled with letters. SBS, single base substitution; DBS, doublet base 505 
substitution; ID, small insertion or deletion. 506 
 507 
Figure 2. Mutation burden versus age for every signature. For every signature, the median 508 
(horizontal bar) and range (vertical bar) in mutation burden for all the crypts from each 509 
individual are shown. Each individual is coloured differently. n=445 crypts from 42 510 
individuals. 511 
 512 
Figure 3. Crypt phylogenies. For selected individuals (a-d), each phylogeny is shown three 513 
times, with branch lengths proportional to SBS (top), DBS (middle), and ID (bottom) 514 
mutation counts. A stacked barplot of the signatures contributing to each branch is 515 
superimposed. The ordering of signatures along branches is for visualisation purposes. “X0” 516 
indicates mutations that could not confidently be assigned to any signature. Phylogenies for 517 
all individuals are shown in Extended Data Fig. 6. Selected phylogenies are dominated by 518 
ubiquitous signatures (a), SBSA and IDA (b), SBSB, DBS8, and IDB (c), or SBSD for the 519 
individual exposed to chemotherapy (d). 520 
 521 
Figure 4. An AXIN2 inactivating mutation. (a) a section after dissection. Red dots 522 
represent crypts with the AXIN2 mutation, blue dots those without it. Crypts without dots 523 
failed sequencing. (b) crypts with the mutation appeared no different to others. (c) CNN-524 
LOH of one crypt over the AXIN2 locus. The copy number state (y axis) for every 525 
chromosome is shown, with one allele coloured red and the other green. (d) Jbrowse image of 526 
reads supporting the AXIN2 mutations. The mutation is red. 25/29 reads support it in the crypt 527 
with CNN-LOH; the four that do not presumably represent stromal contamination. 528 
 529 
 530 
EXTENDED FIGURE LEGENDS 531 
 532 
Extended Data Figure 1. Laser capture microdissection of crypts. (a) a representative 533 
image of a section of colonic tissue, with a magnified inset showing the section before and 534 
after dissection of a crypt. (b-c), the coverage of crypts that underwent whole genome (b) and 535 
targeted (c) sequencing. (d-e), their respective VAF (which is half of the clonal fraction). (f-536 
g), substitutions (f) and indels (g) removed by filtering steps and their mutational spectrum, 537 
arranged as in Figure 1.  538 
 539 
Extended Data Figure 2.  HDP signature extraction results. Results of signature 540 
extraction using an HDP with conditioning on signatures known to be active in colorectal 541 
cancer. For each signature, the extracted signature and the profile of a sample that has a 542 
strong contribution of that signature are shown. Signatures are presented as in Fig. 2. The 543 
HDP extraction was followed by deconvolution by Expectation Maximisation (Methods, 544 
Extended Data Fig. 3) to produce the version of signatures presented in the main text. HDP, 545 
Hierarchical Dirichlet Process. 546 
 547 
Extended Data Figure 3. Expectation maximisation decomposition of HDP signatures. 548 
Three signatures were decomposed. For each panel, the original HDP version in shown on 549 
the top left, the PCAWG signatures that are deemed to contribute at least 10% of mutations to 550 
it on the right, and the reconstituted signature built by combining the PCAWG signatures on 551 
the bottom left. The cosine similarity of the reconstituted signature to the original is shown in 552 
the title to the reconstituted signature plot. HDP, Hierarchical Dirichlet Process; PCAWG, 553 
Pan Cancer Analysis of Whole Genomes. 554 
  555 
Extended Data Figure 4. Validation of single base substitution signatures. Other methods 556 
of signature extraction were run to test the robustness of signature decomposition. a, HDP 557 
without pre-conditioning on PCAWG. b, In-house NNMF without pre-conditioning on 558 
PCAWG. c, NNMF implemented by the MutationalPatterns R package (Methods). HDP, 559 
Hierarchical Dirichlet Process; PCAWG, Pan Cancer Analysis of Whole Genomes; NNMF, 560 
Non-Negative Matrix Factorisation. 561 
 562 
Extended Data Figure 5. Linear modelling of signature accumulation. For signatures that 563 
appeared to show a linear accumulation with age, the mutation rate per site was determined 564 
using mixed models, with age and site as fixed effects, and individual as a random effect. 565 
Confidence intervals were determined by bootstrapping. n=445 crypts from 42 individuals. 566 
Solid lines represent the mean slope of the regression and shaded areas its 95% confidence 567 
intervals. 568 
 569 
Extended Data Figure 6. Crypt phylogenies. (a-ap) For every individual, the phylogeny of 570 
crypts is shown three times: on top, with branch lengths proportional to the number of single 571 
base substitutions; in the middle, with branch lengths proportional to the number of doublet 572 
base substitutions; on the bottom, with branch lengths proportional to the number of small 573 
insertions and deletions. Scale bars are shown on the right-hand side. A stacked barplot of the 574 
mutational signatures that contribute to each branch is overlaid over every branch. “X0” 575 
indicates mutations that could not confidently be assigned to any signature. Please note that 576 
the ordering of signatures along a given branch is just for visualisation purposes: we cannot 577 
distinguish the timing of different signatures along a branch. (aq), Cumulative burden of 578 
SBSA (top panel) and SBSB (bottom panel) is plotted relative to the cumulative burden of 579 
SBS1 in order to time these mutational processes throughout life. Informative clades are 580 
shown (from patients with labelling as in the other panels), with every node and tip of the 581 
clade plotted in the space of the cumulative number of mutations due to a given signature that 582 
have occurred up until that node in the tree. Lines represent the branching structure of the 583 
tree. 584 
 585 
Extended Data Figure 7. Copy number changes and structural variants in normal 586 
colon. 449 crypts had sufficient coverage to be evaluated. (a) whole chromosome 587 
amplifications in five crypts. The copy number state (y axis) for each allele, one coloured red, 588 
and one coloured green, is shown. Chromosomes are labelled along the top of the graph. (b) 589 
timing of copy number changes throughout life. Vertical bars represent 95% confidence 590 
intervals determined by bootstrapping. Horizontal bars represent the most likely time of the 591 
copy number change, as defined by mutationTimeR (Supplementary Results 1) (c), crypts 592 
with loss of heterozygosity. For each chromosome with an LOH event, the copy number 593 
across the whole chromosome is shown in the top part of the panel, with the total copy 594 
number in black and the minor allele copy number in blue. Underneath are shown example 595 
single nucleotide polymorphisms that support the LOH. In each case, reads from the crypt in 596 
question are shown above, and reads from its matched normal are shown underneath. Thus in 597 
the first image, the wild-type state (below) is heterozygous for a T (red) single nucleotide 598 
polymorphism, whereas in the crypt in question (above), this polymorphism has now become 599 
homozygous. Small deviations from a fully homozygous state are likely due to stromal 600 
contamination. (d) reads supporting structural variants in normal colon are shown. 601 
 602 
Extended Data Figure 8. Gain of function driver mutations in normal colon. Putative 603 
driver missense mutations in oncogene hotspots. The number of substitutions catalogued in 604 
COSMIC are shown on the y axis at each position along the gene, with the mutations 605 
observed in our cohort highlighted. 606 
 607 
Extended Data Figure 9. Occurrence matrix of signatures and driver mutations in 608 
crypts. For all crypts that were whole genome sequenced to sufficient depth and for crypts 609 
that underwent targeted sequencing and in which driver mutations were found, the signatures 610 
and driver mutations are shown. Each vertical column represents a crypt. The individual to 611 
which each crypt belongs is indicated by alternating colours in the top bar. The site to which 612 
each crypt belongs is shown underneath. The matrix is coloured by contribution of each 613 
signature to each crypt, normalised for each signature; thus the crypt with the largest 614 
contribution of a given signature is coloured purple, and the crypt with the smallest 615 
contribution is coloured white. Crypts in which the signatures could not be assessed, either 616 
because they underwent targeted sequencing or the coverage was poor, are coloured grey. 617 
Driver mutations, including heterozygous mutations in tumour suppressor genes, are 618 
indicated by a black bar. 619 
 620 
Extended Data Figure 10. Stem cell dynamics of normal colon (Supplementary Results 2). 621 
(a) stem cell number and stem cell replacement rate in normal human colonic crypts, as 622 
estimated by approximate Bayesian computation. Every point represents a simulation. Points 623 
are coloured according to their similarity to the observed data: the most similar 0.1% are 624 
coloured dark red, and so on, until the least similar simulations are blue. (b) approximate 625 
Bayesian computation of the crypt fission rate in the human colon. The prior distribution of 626 
the crypt fission rate used to simulate many biopsies of the colon is shown above. The unit 627 
for the crypt fission rate is fissions per crypt per year. The posterior distribution of the crypt 628 
fission rate parameter estimated by neural network regression on the simulations is shown 629 
below. (c-d), evidence of crypt fusion in human colon. In each figure, above is shown a 630 
phylogeny that depicts the genetic relationships between selected crypts. Dotted blue lines 631 
show low allele fraction mutations that are shared between crypts in a manner that is 632 
incompatible with phylogeny that is dictated by the clonal mutations. Underneath each crypt 633 
in the phylogeny is an image depicting its position in the section. Sections are labelled 634 
according to their z-stacked order. Beneath this, the allele fraction of mutations on each 635 
branch of the phylogeny in each crypt is shown. To the right hand side is the trinucleotide 636 
context of the mutations that occurred on the branch. 637 
 638 
Extended Data Figure 11. Comparison of the mutational signatures and driver 639 
landscape of normal crypts and colorectal adenocarcinomas. (a) a comparison of the 640 
burden of mutations due to every mutational signature found in either group. For each 641 
signature, the (mutation burden+1) of every sample is shown on the y axis on a log scale. 642 
Normal colon and cancer samples are ordered within their groups. Colorectal 643 
adenocarcinoma signature attributions and burden are from Alexandrov et al.1. 60 cancers are 644 
compared with 472 normal crypts. (b) the proportion of driver mutations in each gene in 645 
normal colon and colorectal cancer. The frequency of driver mutations in cancer was derived 646 





SUPPLEMENTARY METHODS 652 
 653 
Human tissues 654 
We obtained healthy colonic biopsies from four cohorts (Supplementary Table 1). The first 655 
represents seven deceased organ donors ranging in age from 36 to 67, from whom colonic 656 
and small intestinal biopsies were taken at the time of organ donation (REC 15/EE/0152). 657 
The second represents individuals aged 60 to 72 who were having a colonoscopy following a 658 
positive faecal occult blood test as part of the Bowel Cancer Screening Programme (Ethical 659 
approval 08-H0308-13); we selected 16 who were not found to have either an adenoma or a 660 
carcinoma on colonoscopy, and 15 who were found to have a colorectal carcinoma (the 661 
normal biopsies that we use were distant from these lesions). The third cohort represents 662 
three paediatric patients who underwent routine colonoscopy to exclude inflammatory bowel 663 
disease and who were found to have a completely normal intestinal mucosa macroscopically 664 
and histologically (REC 12/EE/0482). The final cohort included one 78 year-old gentleman 665 
with oesophageal cancer who underwent a warm autopsy (REC 13/EE/0043).  This 666 
gentleman had been treated with palliative chemotherapy of Epirubicin, Oxaliplatin and 667 
Capecitabine within the three months before the autopsy; given that monoclonal conversion 668 
within crypts is on the order of years, mutations due to these chemotherapies are likely to be 669 
private to a small proportion of stem cells per crypt and so are unlikely to be detected. All 670 
samples were obtained with informed consent and studies approved by East of England 671 
Research Ethics Committees. 672 
 673 
Laser capture microdissection of colonic crypts 674 
Fresh frozen biopsies were embedded in optimal cutting temperature (OCT) compound. 30 675 
micrometre sections were fixed in methanol for five minutes, washed three times with 676 
phosphate-buffered saline, and stained with Gill’s haematoxylin for 20 seconds. Crypts were 677 
isolated by laser capture microdissection, and collected in separate wells of a 96-well plate. 678 
They were lysed using the Arcturus PicoPure Kit (Applied Biosystems) according to the 679 
manufacturer’s instructions. DNA library prep then proceeded without clean-up or 680 
quantification. 681 
 682 
Library preparation 683 
Two library preparation methods were used for laser capture microdissected (LCM) material: 684 
in initial experiments sonication was used to fragment DNA, and later, an enzymatic 685 
fragmentation method was implemented as it could make libraries from even lower input. 686 
Comparison of the two methods showed no difference in mutation calls once post-processing 687 
filters (described below) had been implemented. All samples in this study were processed 688 
using an Agilent Bravo Workstation (Option B; Agilent Technologies).  689 
 690 
For sonication libraries, LCM lysate (20 μl) was mixed with 100 μl TE buffer (Ambion; 10 691 
mM Tris-HCl, 1 mM EDTA) and DNA was fragmented using focused acoustics (Covaris 692 
LE220; Covaris, Inc.).  Fragmented DNA was mixed with 80 μl Ampure XP beads (Beckman 693 
Coulter).  Following a 5 min binding reaction and magnetic bead separation, genomic DNA 694 
was washed twice with 75% ethanol.  Beads were resuspended in 20 μl nuclease-free water 695 
(Ambion) and processed immediately for DNA library construction. Each sample (20 μl) was 696 
mixed with 2.8 μl of NEBNext Ultra II End Prep Reaction Buffer, 1.25 μl of NEBNext Ultra 697 
II End Prep Enzyme Mix (New England BioLabs) and incubated on a thermal cycler for 30 698 
min at 20°C then 30 min at 65°C.  Following DNA fragmentation and A-tailing, each sample 699 
was incubated for 20 min at 20°C with a mixture of 30 μl ligation mix and 1 μl ligation 700 
enhancer (New England BioLabs), 0.9 μl nuclease-free water (Ambion) and 0.1 μl duplexed 701 
adapters (100 uM; 5’-ACACTCTTTCCCTACACGACGCTCTTCCGATC*T-3’, 5’-phos-702 
GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’).  Adapter-ligated libraries were 703 
purified using Ampure XP beads by addition of 65 μl Ampure XP solution (Beckman 704 
Coulter) and 65 μl TE buffer (Ambion).  Following elution and bead separation, DNA 705 
libraries (21.5 μl) were amplified by PCR by addition of 25 μl KAPA HiFi HotStart 706 
ReadyMix (KAPA Biosystems), 1 μl PE1.0 primer (100 μM; 5'-707 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGA708 
TC*T-3') and 2.5 μl iPCR-Tag (40 μM; 5’-709 
CAAGCAGAAGACGGCATACGAGATXGAGATCGGTCTCGGCATTCCTGCTGAACC710 
GCTCTTCCGATC-3’) where ‘X’ represents one of 96 unique 8-base indexes The sample 711 
was then mixed and thermal cycled as follows: 98 °C for 5 min, then 12 cycles of 98 °C for 712 
30 s, 65°C for 30 s, 72 °C for 1 min and finally 72 °C for 5 min. Amplified libraries were 713 
purified using a 0.7:1 volumetric ratio of Ampure Beads (Beckman Coulter) to PCR product 714 
and eluted into 25 μl of nuclease-free water (Ambion).  DNA libraries were adjusted to 2.4 715 
nM and sequenced on the HiSeq X platform (illumina) according to the manufacturer’s 716 
instructions with the exception that we used iPCRtagseq (5’-717 
AAGAGCGGTTCAGCAGGAATGCCGAGACCGATCTC-3’) to read the library index.  718 
 719 
For enzymatic fragmentation, LCM lysate (20 ul) was mixed with 50 ul Ampure XP beads 720 
(Beckman Coulter) and 50 μl TE buffer (Ambion; 10 mM Tris-HCl, 1 mM EDTA) at room 721 
temperature.  Following a 5 min binding reaction and magnetic bead separation, genomic 722 
DNA was washed twice with 75% ethanol.  Beads were resuspended in 26 μl TE buffer and 723 
the bead/genomic DNA slurry was processed immediately for DNA library construction. 724 
Each sample (26 μl) was mixed with 7 μl of 5X Ultra II FS buffer, 2 μl of Ultra II FS enzyme 725 
(New England BioLabs) and incubated on a thermal cycler for 12 min at 37°C then 30 min at 726 
65°C.  Following DNA fragmentation and A-tailing, each sample was incubated for 20 min at 727 
20°C with a mixture of 30 μl ligation mix and 1 μl ligation enhancer (New England 728 
BioLabs), 0.9 μl nuclease-free water (Ambion) and 0.1 μl duplexed adapters (100 uM; 5’-729 
ACACTCTTTCCCTACACGACGCTCTTCCGATC*T-3’, 5’-phos-730 
GATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’).  Adapter-ligated libraries were 731 
purified using Ampure XP beads by addition of 65 μl Ampure XP solution (Beckman 732 
Coulter) and 65 μl TE buffer (Ambion).  Following elution and bead separation, DNA 733 
libraries (21.5 μl) were amplified by PCR by addition of 25 μl KAPA HiFi HotStart 734 
ReadyMix (KAPA Biosystems), 1 μl PE1.0 primer (100 μM; 5'-735 
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGA736 
TC*T-3') and 2.5 μl iPCR-Tag (40 μM; 5’-737 
CAAGCAGAAGACGGCATACGAGATXGAGATCGGTCTCGGCATTCCTGCTGAACC738 
GCTCTTCCGATC-3’) where ‘X’ represents one of 96 unique 8-base indexes The sample 739 
was then mixed and thermal cycled as follows: 98 °C for 5 min, then 12 cycles of 98 °C for 740 
30 s, 65°C for 30 s, 72 °C for 1 min and finally 72 °C for 5 min. Amplified libraries were 741 
purified using a 0.7:1 volumetric ratio of Ampure Beads (Beckman Coulter) to PCR product 742 
and eluted into 25 μl of nuclease-free water (Ambion).  DNA libraries were adjusted to 2.4 743 
nM and sequenced on the HiSeq X platform (Illumina) according to the manufacturer’s 744 
instructions with the exception that we used iPCRtagseq (5’-745 
AAGAGCGGTTCAGCAGGAATGCCGAGACCGATCTC-3’) to read the library index.  746 
 747 
Whole genome sequencing  748 
We generated paired end sequencing reads (150bp) using Illumina XTEN® machines 749 
resulting in ~15x coverage per sample. In 94% of the whole genome crypts included for 750 
statistical analysis, over 90% of the callable genome was covered by more than 10 reads. 751 
Sequences were aligned to the human reference genome (NCBI build37) using BWA-MEM.  752 
 753 
Targeted sequencing 754 
A 2.3 MB capture panel was designed in-house to pull down genes that are known or 755 
suspected to play a role in neoplasia. We performed custom RNA bait design following the 756 
manufacturer’s guidelines (SureSelect, Agilent). Samples were multiplexed on flow cells and 757 
subjected to paired end sequencing (75-bp reads) using Illumina HiSeq2000 machines. One 758 
96-well plate of samples was sequenced on each lane, but as tissue recovery was variable, a 759 
range of coverage was achieved.  Sequences were aligned to the human reference genome 760 
(NCBI build37) using BWA-align. 761 
 762 
Data Availability 763 
Whole genome and targeted sequencing data are deposited in the European Genome 764 
Phenome Archive (EGA) with EGA accession EGAD00001004192 and EGAD00001004193. 765 
Images of microdissections and the physical distances between crypts are available on 766 
Mendeley Data by searching for the title of this article. All other data is available from the 767 
authors on request. 768 
 769 
Code Availability 770 
Code for statistical analyses is provided as part of the supplement. Custom R scripts and their 771 
input data for signature analysis are available on GitHub at https://github.com/HLee-772 
Six/colon_microbiopsies. All other code is available from the authors on request.  773 
 774 
Calling substitutions 775 
Substitution calling was broken down into three steps: mutation discovery; filtering to 776 
produce a list of clean sites; and genotyping, where the presence or absence of every 777 
mutation in every sample is evaluated.  778 
 779 
First, mutations were initially discovered using the Cancer Variants through Expectation 780 
Maximisation (CaVEMan) algorithm46. CaVEMan uses a naïve Bayesian classifier to derive 781 
the probability of all possible genotypes at each nucleotide. CaVEMan copy number options 782 
were set to major copy number 5 and minor copy number 2 for normal clones, as in our 783 
experience this maximises sensitivity. The algorithm was run using an unmatched normal in 784 
order to be able to derive phylogenies: had another sample from the same individual been 785 
treated as a matched normal, early embryonic mutations would have been treated as germline 786 
and discarded, resulting in incorrect trees.  787 
 788 
Second, a number of post-processing filters were applied (Extended Data Figure 2). These 789 
included filtering against a panel of 75 unmatched normal samples to remove common single 790 
nucleotide polymorphisms, post-processing as described previously32 and two filters (only 791 
applied to whole genome sequencing data) designed to remove mapping artefacts associated 792 
with BWA-MEM: the median alignment score of reads supporting a mutation should be 793 
greater than or equal to 140, and fewer than half of these reads should be clipped. The library 794 
preparation protocol for microbiopsies produced shorter library insert sizes than standard 795 
methods. Reads could therefore overlap, resulting in double counting of mutant reads. 796 
Fragment-based statistics were generated to prevent the calling of variant supported by a low 797 
number of fragments. Variants were annotated by ANNOVAR47 and fragment-based 798 
statistics (fragment coverage, number of fragments supporting the variant, fragment-based 799 
allele fraction) were calculated for each variant after the exclusion of marked PCR duplicates. 800 
In the rare event of discordance in the called base at the variant position between overlapping 801 
paired-end reads, the base with the highest quality score was selected. Fragment-based 802 
statistics were calculated separately for high quality fragments (alignment score ≥ 40 and 803 
base scores ≥ 30). Variants supported by at least three high quality fragments were retained 804 
and used for the next stage of variant filtering. Inspection of variants specific to LCM 805 
experiments revealed that the vast majority were present within inverted repeats capable of 806 
forming hairpin structures, that they were supported by reads with very similar alignment 807 
start position (and so not marked as PCR duplicates), and were primarily located close to the 808 
alignment start within the supporting reads. Commonly these variants coincided with other 809 
proximal variants (1-30 bp), but filtering based on variant proximity would also remove 810 
actual kataegis events. In silico modelling of the potential hairpin showed that the variants 811 
were aligning to each other in the stem of the structure, but could not form a base pair, while 812 
all other bases could. The artefacts are likely the consequence of erroneous processing of 813 
cruciform DNA (existing either prior to DNA isolation or formed during library preparation) 814 
by the enzymatic digestion protocol applied. We have considered modelling the hairpin 815 
structures to filter these variants, but given the fact that read clustering (i.e., similar alignment 816 
position) serves as a hallmark for these artefacts, we opted to use the proximity of the variant 817 
to the alignment start, and the standard deviation (SD) and median absolute deviation (MAD) 818 
of the variant position within the supporting reads, as features for filtering. These statistics 819 
were calculated separately for positive and negative strand aligned reads. In case the variant 820 
was supported by a low number of reads (i.e., 0-1 reads) for one of the strands, the filtering 821 
was based only on the statistics generated for the other strand. Per variant, if one of the 822 
strands had too few reads supporting, it was required for the other strand that either: (I) there 823 
should be ≤ 90% supporting reads to report the variant within the first 15% of the read 824 
starting from the alignment start, or (II) the statistics MAD > 0 and SD > 4. Per variant, if 825 
both strands were supported by sufficient reads it was required for both strands separately 826 
that either: (I) there should be ≤ 90% supporting reads to report the variant within the first 827 
15% of the read, (II) the statistics MAD > 2 and a SD > 2, or (III) that the other strand should 828 
have the statistics MAD > 1 and SD > 10 (i.e., the variant is retained if the other strand 829 
demonstrates strong measures of variance). In our experience, the proposed strategy vastly 830 
reduces the number of artefactual variants while retaining all other variants, as assessed by 831 
running the last filtering step on WGS data from non-LCM experiments. 832 
 833 
Third, mutations were genotyped in every sample. A pileup of all the samples from a given 834 
individual was constructed, counting the number of mutant and wild type reads in every 835 
sample over every site that had been called in any sample from that person. Only reads with a 836 
mapping quality of 30 or above and bases with a base quality of 30 or above were counted. 837 
After applying these filters, mutations were genotyped based on the number of mutant and 838 
wild type reads at each locus. Mutations were called based on a variant allele fraction (VAF) 839 
> 0.2, a depth > 7, and at least 4 mutant reads. If the depth over a locus was less than seven in 840 
a given sample, or if there was more than one mutant read but the other criteria were not met, 841 
the genotype was set to NA for tree construction purposes. Loci that were set to NA in more 842 
than one third of the samples were removed for construction of the phylogeny. Positions were 843 
called as germline if they were either called as present or NA in all of the samples from a 844 
given individual. 845 
 846 
1.2% of all mutations were present in the coding regions of the genome. All mutations in 847 
coding regions are provided (Supplementary Table 3). 848 
 849 
 850 
  851 
Calling short insertions and deletions (indels) 852 
As for substitutions, calling of indels was broken down into mutation discovery, filtering, and 853 
genotyping. Mutations were called with the Pindel algorithm48 using an unmatched normal. 854 
Post processing filters were applied as in Nik-Zainal et al.32, and the number of mutant and 855 
wild-type reads was tabulated as above. The same dataset-specific filters were applied as for 856 
substitutions. Indels were then genotyped based on a VAF>0.2, a depth of at least 10, and 857 
support of at least 5 mutant reads. 858 
 859 
Calling structural variants 860 
Genomic rearrangements were called using the BRASS algorithm 861 
(https://github.com/cancerit/BRASS). Abnormally paired read pairs from WGS were grouped 862 
and filtered by read remapping. Read pair clusters with ≥50% of the reads mapping to 863 
microbial sequences were removed, as were rearrangements where the breakpoint could not 864 
be reassembled. Candidate breakpoints were matched to copy number breakpoints defined by 865 
ASCAT (see below) within 10kb. Only structural variants where the two breakpoints were 866 
more than 1000 base pairs apart were considered. Structural variants were called against a 867 
matched normal skin or blood sample when available and against another crypt from the 868 
same individual with good coverage when not. 869 
 870 
Calling copy number 871 
Copy number changes were called using the Allele-Specific Copy number Analysis of 872 
Tumours (ASCAT) algorithm49. The same matched normal sample was used as for calling 873 
structural variants. For additional validation of copy number changes in normal colon, the 874 
QDNAseq algorithm50 was run. ASCAT uses both the read depth and ratios of heterozygous 875 
single nucleotide polymorphisms to determine an allele-specific copy number, while the 876 
QDNAseq relies solely on variations in sequencing coverage. To call amplifications and 877 
deletions in the colonic microbiopsy cohort, only those that were both called by ASCAT and 878 
showed a clear departure from the background log2ratio by QDNAseq were retained.  To call 879 
copy neutral loss of heterozygosity in this cohort, all such events called by ASCAT were 880 
checked visually on Jbrowse51 to verify an imbalance of parental snps. Only crypts with 881 
>10X coverage, for which copy number changes could be reliably detected, were used. 882 
 883 
Detection of driver variants and positive selection 884 
Driver mutations were detected both through an unbiased dNdS method and through manual 885 
annotation. For these analyses, the CaVEMan and Pindel calls were used without post-886 
processing filters (such as requiring a VAF cutoff of >0.2) in order to maximise our 887 
sensitivity. All putative driver variants were visually inspected using Jbrowse51, and so we 888 
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dNdScv52 was used to conduct three tests: first, using only the whole genome sequencing 891 
data, an analysis of selection over all genes; second, using combined whole genome and 892 
targeted sequencing data, over all the genes covered by the bait-set; and finally, using again 893 
this combined dataset, over 90 selected cancer genes (Supplementary Table 4, Supplementary 894 
Results 1). 895 
 896 
Manual annotation of driver variants based on prior knowledge complemented this. A list of 897 
90 colorectal cancer genes (appendix) curated from the literature that were also covered by 898 
the bait-set were intersected with the list of substitutions and indels from combined whole 899 
genome and targeted sequencing. Mutations were annotated as putative drivers if they were 900 
either missense mutations that fell in an oncogene hotspot (based on visualisation of the 901 
distribution of mutations in the gene on COSMIC53), or if they were truncating mutations that 902 
fell in a tumour suppressor gene. 903 
 904 
Structural variants that might act as drivers were assessed by intersection of genes involved 905 
in each structural variant with the twelve genes involved in gene fusions that have been 906 
reported in colorectal cancer in COSMIC (VTI1A, TCF7L2, TPM3, NTRK1, PTPRK, RSPO3, 907 
ETV6, NTRK3, EIF3E, RSPO2, C2orf44, and ALK). No fusion genes were found. None of the 908 
genes involved in structural variants in our data overlapped with the list of 90 cancer genes 909 
used for assessing substitutions and indels, and nor were there any genes that were affected 910 
by more than one structural variant. No high-level copy number amplifications were observed 911 
and there were no homozygous deletions. 912 
 913 
Please note that the driver frequency is low, such that we cannot estimate a per-gene driver 914 
frequency. All we can do to derive a meaningful estimate is to pool our driver mutations.  In 915 
addition, coverage may fluctuate even within a gene. Some portions of a gene may be well 916 
covered in 1,000 crypts, and others in 2,000 crypts. The approach that we took was to 917 
calculate, for the average exonic base pair in our 90 cancer genes, the number of crypts in 918 
which that base pair was covered by >=8 reads (for substitutions) and by >=10 reads (for 919 
indels).  64% of all bases in the targeted panel across all crypts are covered by >=8 reads, 920 
which equates to a number of callable bases equivalent to having sequenced ~1,400 crypts 921 
with perfect coverage over every base in every crypt. This average number of crypts in which 922 
all base pairs achieve good coverage becomes the denominator for calculating the driver 923 
mutation frequency (with the number of drivers observed in the dataset as the numerator). A 924 
similar approach can be taken with indels.  Our estimate of 1% uses a global correction, on 925 
the assumption that under-representation and over-representation will even itself out when 926 
estimating the total frequency of driver mutations in the whole dataset.  927 
 928 
Estimation of frequency of driver mutations in cancer 929 
Publically-available colorectal cancer mutation calls were obtained from The Cancer Atlas 930 
Network37. Driver mutations were annotated manually in the same way as in our dataset: only 931 
mutations that fell in the 90 genes that we had selected were considered, and they were 932 
annotated as putative drivers if they were either missense mutations that fell in an oncogene 933 
hotspot (based on visualisation of the distribution of mutations in the gene on COSMIC53), or 934 
if they were truncating mutations that fell in a tumour suppressor gene. 935 
 936 
Construction of phylogenies 937 
Phylogenies are used in this analysis for timing mutations. The most informative branches in 938 
this case are the long branches shared by a small number of crypts, which are very robust to 939 
all tree construction methods. Trees were built using maximum parsimony using substitutions 940 
called as described above. For every individual, the input matrix of mutation calls was 941 
bootstrapped 100 times. Phylogenies were constructed for each replicate using the Wagner 942 
method of the Mix programme from the Phylip suite of tools54. The consensus phylogeny was 943 
constructed from 100 bootstrap runs using the extended majority rule method for the 944 
Consense programme from the Phylip suite of tools54. 945 
Across all phylogenies, a mean of 10% and a median of 1.5% of mutations per tree 946 
did not fit the trees perfectly. Phylogenies with more crypts had more mutations that fitted 947 
imperfectly. Consider a mutation that is really present in 50 crypts. Even with 15X coverage 948 
over the site in every sample, and with every crypt completely clonal, if we simulate 949 
resampling of mutant reads from the binomial distribution (with size of 15 and probability of 950 
0.5), 17% of the time the mutation will have fewer than the 3 reads required to call it in at 951 
least one sample. Variation in sequencing depth, clonality, and sequencing errors would 952 
further decrease the probability of calling the mutation perfectly in every sample. Nodes 953 
across all our phylogenies had mean bootstrapping values of 0.77 and median bootstrapping 954 
values of 0.99. Branches at the very top of the phylogenies, likely representing embryonic 955 
cell divisions, are supported by only a few mutations and have lower support because in a 956 
given bootstrap sample the couple of mutations that support this node may be omitted. 957 
Longer shared branches almost always have bootstrapping values of 1. These longer shared 958 
branches are those that are most important to our analyses, because they are the most 959 
informative when timing mutational signatures relative to one another and because they 960 
represent postnatal crypt fission events. In order to increase further our confidence in our 961 
phylogenies, we validated them by reconstructing them with indels. To do this, the same 962 
procedure as for substitutions was followed for indel matrices. As there were fewer indels 963 
than substitutions, nodes in indel phylogenies were generally reconstructed with lower 964 
confidence than in substitution phylogenies, but they broadly agree. 85% of nodes 965 
reconstructed with >=90% confidence in the indel tree were present with exactly the same set 966 
of descendants in the substitution trees. Any errors in the phylogenies should be relatively 967 
minor and not affect our downstream analyses. 968 
 969 
The phylogeny inference programme used provided the topology of the tree but not the 970 
assignment of mutations. Mutations from the input matrix of genotypes therefore have to be 971 
re-assigned to branches. In order to assign a set of mutation calls with no false negative and 972 
no false positives to a tree, each branch of the tree was considered in turn. If a mutation was 973 
called in all the descendants of a given branch, and in no samples that were not descendants 974 
of the branch, mutations were assigned to that branch.  975 
 976 
Some colonic microbiopsies suffered from low coverage and stromal contamination. For this 977 
reason, we did not expect mutations to fit the tree perfectly, as a mutation that was truly 978 
present in a colony might be missed if too few supporting reads are found. Mutations were 979 
only assigned to the tree in order to determine the mutational processes active at a particular 980 
time. We reasoned that it was preferable to assign only mutations that fit the tree perfectly 981 
and adjust the branch lengths based on the power to call mutations at a given branch, rather 982 
than attempting to assign mutations that fit the tree imperfectly. Using the clonality and 983 
coverage of all descendants of a branch, the proportion of true substitutions or indels on the 984 
branch that would be first discovered (whether by CaVEMan or Pindel) and then genotyped 985 
as present according to the criteria described above was calculated. The observed branch 986 
length was then adjusted by dividing by this proportion. Adjustment proportions can be found 987 
in Supplementary Table 7. This was done for both substitutions and indels, but not for 988 
structural variants and for larger copy number changes due to a lack of data: most branches 989 
have no large variants and so could not be extended appropriately.  Rearrangements and copy 990 
number changes were assigned to phylogenies manually. 991 
 992 
 993 
Extraction of mutational signatures 994 
Mutational signatures were extracted using the mutations assigned to every branch of a 995 
phylogeny as a ‘sample’. This allows better discrimination of mutational processes that may 996 
occur at different times within the same cell. Mutations were categorised following the 997 
method used by the Mutational Signatures working group of the Pan Cancer Analysis of 998 
Whole Genomes (PCAWG)1. Single base substitutions were categorised into 96 classes 999 
according the identity of the pyrimidine mutated base pair, and the base 5’ and 3’ to it. 1000 
Doublet base substitutions were categorised into 78 classes according to the identity of the 1001 
reference and alternative bases. Indels were classified according to whether they were an 1002 
insertion or a deletion, the identity of the inserted/deleted base, the length of the 1003 
mononucleotide tract in which they occurred, or the degree of homology with the 1004 
surrounding sequence into 83 classes (Fig. 1a). 1005 
 1006 
Signatures were extracted using a hierarchical Dirichlet Process55,56. Code and the input 1007 
mutations are provided at https://github.com/HLee-Six/colon_microbiopsies. First, the 1008 
algorithm was conditioned on the set of mutational signatures that have found to be operative 1009 
in colorectal cancers in PCAWG1: SBS1, SBS2, SBS3, SBS5, SBS13, SBS16, SBS17a, 1010 
SBS17b, SBS18, SBS25 (included although it is not found in colorectal cancer because the 1011 
similarity with the mutational profile with crypts from one individual had been previously 1012 
noted), SBS28, SBS30, SBS37, SBS40, SBS41, SBS43, SBS45, SBS49, DBS, DBS3, DBS4, 1013 
DBS6, DBS7, DBS8, DBS9, DBS10, DBS11, ID1, ID2, ID3, ID4, ID5, ID6, ID7, ID8, ID10, 1014 
and ID14. This allows simultaneous discovery of new signatures and matching to known 1015 
ones. Nine single base substitution (SBS), two doublet base substitution (DBS), and five 1016 
indel (ID) signatures were discovered (Extended Data Fig. 2). Despite pre-conditioning, 1017 
signatures that were perfectly correlated in all samples were still amalgamated. This 1018 
occurred, for example, with signatures 1, 5, and 18. Therefore, expectation maximisation was 1019 
used to deconvolute all HDP signatures into known PCAWG signatures. If a signature 1020 
reconstituted from the components that expectation maximisation extracted (only including 1021 
PCAWG signatures that accounted for at least 10% of mutations in each sample to avoid 1022 
over-fitting) had a cosine similarity to the HDP signature of more than 0.95, the signature 1023 
was presented as its expectation maximisation deconvolution. Three HDP signatures met 1024 
these criteria: the HDP SBS1 signature was deconvoluted into a mixture of PCAWG SBS1, 1025 
PCAWG SBS5, and PCAWG SBS18; the HDP DBSA was deconvoluted in PCAWG DBS2, 1026 
PCAWG DBS4, PCAWG DBS6, PCAWG DBS9, and PCAWG DBS11; and the HDP IDC 1027 
was deconvoluted into PCAWG ID1, PCAWG ID2, and PCAWG ID5 (Extended Data Fig. 1028 
3). To test the robustness of this signature analysis, other signature extraction methods were 1029 
used: HDP with no pre-conditioning, the non-negative matrix factorisation (NNMF) method 1030 
used by Blokzijl and colleagues4, and a version of the NNMF algorithm used by Alexandrov 1031 
and colleagues1. These all produced comparable results (Extended Data fig. 4). 1032 
 1033 
Timing SBSA and SBSB throughout life  1034 
Five patients had informative clades with branchpoints that allowed us to time SBSA. 1035 
Plotting the cumulative amount of SBSA vs SBS1 at each node in these clades (Extended 1036 
Data Fig. 6aq), we observed that for each the rate of accumulation of SBSA relative to SBS1 1037 
was high in early branchpoints, and then slowed down almost to zero on all branches but for 1038 
one (a branch of patient ao, where it continues to be acquired, albeit at a slow rate).  1039 
 1040 
We can take the inflexion point on the graph of cumulative SBSA vs SBS1 to be the upper 1041 
limit of the point in time when SBSA slowed down. This provides an upper bound because: 1042 
 1043 
1. When we observe the presence of a signature on a branch, we know that the causative 1044 
process must have been active at some point during the lifetime of the branch, but we 1045 
cannot say when on the branch it occurs; it might have ended long before the branch 1046 
did. 1047 
2. If the time to the most recent common ancestor of the crypt is longer than 0, the age at 1048 
which this stopped would be earlier. 1049 
3. If the SBS1 mutation rate is increased in early life, as it may be during the rapid 1050 
growth of the embryo, the age at which the inflexion point occurs would have been 1051 
younger. 1052 
 1053 
Using these five informative clades, and assuming a clock-like but personalised rate of SBS1 1054 
accumulation (i.e. each patient can accumulate SBS1 at their own constant rate), we found 1055 
that the upper bound of the age at which SBSA slowed was: 9.7 years (patient h); 7.1 years 1056 
(patient z); 2.4 years (patient am); 20.1 years (patient aa); and 9.6 years (patient ao). There 1057 
are no branches that begin after 10 years of age with a high ratio of SBSA to SBS1. 1058 
 1059 
The most informative branchpoint is the earliest inflexion point; the estimate of 2.4 years 1060 
from patient aa, is therefore, perhaps our best estimate. Nonetheless, we did not want to base 1061 
our statement on a single patient, and so 10 years was given in the text as four patients had 1062 
branches that ended before 10 years of age. 1063 
 1064 
A similar argument can be made for SBSB (Extended Data Fig. XXX). For SBSB, however, 1065 
only two clades were informative. The estimated upper bounds of age for SBSB activity were 1066 
2.4 years old (this was the same inflexion point as for SBSA in patient aa), and 6.4 years old 1067 
(patient ai). For patient ai, a reasonable amount of SBSB is still acquired after this 1068 
branchpoint. If the ratio of accumulation of SBSB vs SBS1 continued at the same rate as 1069 
before this branchpoint, the number of SBSB mutations seen in the terminal branches would 1070 
have been observed by age 8.2 years old. 1071 
 1072 
Telomere length analysis 1073 
Telomere length was estimated from whole genome sequencing data using Telomerecat. 1074 
Telomerecat is a python based software package for telomere length estimation from  short-1075 
read whole genome sequence data57. It functions by classifying paired-end reads as either 1076 
fully or partially telomeric based on the canonical hexamer TTAGGG, and uses that ratio to 1077 
estimate an average telomere length. Notably, Telomerecat measures telomeres and also 1078 
accounts for interstitial telomeric repeats. It is ploidy and species agnostic (assuming that the 1079 
telomere hexamer is the canonical mammalian signature of TTAGGGn). Telomerecat has 1080 
four main stages; 1) Identification of all telomeric or partially telomeric read pairs and 1081 
creation of a subsetted bam file containing only these reads 2) Classification of telomeric 1082 
read-pairs into intratelomeric, boundary or junction-spanning or intrachromosomal 3)Error 1083 
correction of boundary or junction-spanning read pairs 4) Estimation of telomere length 1084 
based on the ratio of intratelomeric and boundary / junction spanning read pairs.  1085 
 1086 
Telomerecat has been validated on whole genome DNA sequencing files from both tumour 1087 
and normal samples57. Its results show concordance with an established method of telomere 1088 
length measurement; the mean Telomere Restriction Fragment (mTRF) technique. 1089 
Alternative packages are available notably: Computel58, Telseq59 and TelomereHunter60. 1090 
They all have respective strengths and have been benchmarked through their methods 1091 
publications. We have opted for Telomerecat as it provides a base pair resolution estimate of 1092 
telomere length whilst providing correction for variations in sequencing depth in a ploidy 1093 
agnostic manner.  1094 
 1095 
We have run Telomerecat on 445 crypt bam files with good coverage and clonality to 1096 
generate telomere length estimates. Telomerecat was threaded across 10 cores and 100 1097 
simulation cycles were requested per run. Values displayed are the median telomere length 1098 
across all chromosomes in that samples measured in base pairs. 1099 
 1100 
Statistical analyses 1101 
All statistical analyses were performed in R (Supplementary Results 1, Supplementary 1102 
Results 2). Code can be found at https://github.com/HLee-Six/colon_microbiopsies. 1103 
 1104 
 1105 
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